2020-02-12T12:55:34-06:00 2019-09-30 930623286 ALDRICH CPAS AND ADVISORS LLP 7676 HAZARD CENTER DRIVE STE 1300 SAN DIEGO CA 92108 990 2018-10-01 330189397 VETERANS MEDICAL RESEARCH FOUNDATION OF SAN DIEGO VETE 8586423070 3350 LA JOLLA VILLAGE DR BLDG 13 SAN DIEGO CA 92161 MARIA SITTMANN EXECUTIVE DIRECTOR/CEO 8586423375 2020-02-04 1 ELSA A ROMERO P00485021 6198104940 2020-02-04 50.234.117.166 2020-02-04 08:48:21 PS P B7D6BDC56C700C8BB44457ECED8C1851ADEC8FFC 200C14A4C1642EF3ABF725493CD0BA4EE178CDEC 2018 2020-11-06 18:47:13Z MARIA SITTMANN 3350 LA JOLLA VILLAGE DR BLDG 13 SAN DIEGO CA 92161 14851993 0 X WWW.VMRF.ORG X 1989 CA TO ENHANCE THE HEALTH OF VETERANS OF ALL GENERATIONS THROUGH RESEARCH AND EDUCATION. 14 13 194 14 0 0 11430758 9887982 4576532 4943731 12923 20280 0 0 16020213 14851993 0 0 0 0 11986078 10942612 0 0 0 5131289 4204891 17117367 15147503 -1097154 -295510 6101482 6701268 2989202 3884498 3112280 2816770 X HONORING MILITARY SERVICE WITH SCIENCE; OUR BENCH-TO-BEDSIDE APPROACH HAS LED TO BREAKTHROUGHS IN AREAS SUCH AS SHINGLES PREVENTION, HEART DISEASE, METABOLIC DISEASES AND GROUND BREAKING WORK ON POST-TRAUMATIC STRESS DISORDER. 0 0 1352295 DR. GUATELLI-ENHANCEMENT OF INFECTIVITY BY HIV-1 VIA ANTAGONISM OF SERINC PROTEINS. THE PURPOSE OF THIS PROJECT IS TO 1) COMBINE OUR BIOCHEMICAL, CELL BIOLOGIC, AND VIROLOGIC ASSAYS TO VALIDATE AND ELABORATE THESE MECHANISMS 2) DETERMINE THE STRUCTURAL BASIS OF SERINC ANTAGONISM BY NEF. WE AIM TO PROVIDE HIGH-RESOLUTION STRUCTURES OF THE INTERACTION OF NEF WITH SERINC PROTEINS AND CLATHRIN ADAPTORS. 3) DETERMINE HOW SERINC PROTEINS AFFECT INFECTIVITY IN AN ENV-DEPENDENT MANNER. TO FACILITATE AN UNDERSTANDING OF SERINC FUNCTION, WE WILL CHARACTERIZE A FULL-LENGTH PROTEIN BIOPHYSICALLY AND AIM TO PROVIDE A HIGH-RESOLUTION STRUCTURE. WE WILL TEST THE HYPOTHESIS THAT SERINC PROTEINS INTERACT WITH ENV TO INHIBIT INFECTIVITY AND MAP THE INTERACTION. WE WILL DETERMINE WHETHER SERINC PROTEINS AFFECT THE CONFORMATION OF ENV TRIMERS AS DISPLAYED ON THE CELL SURFACE AND ON VIRIONS. LASTLY, WE WILL ELABORATE A MODEL IN WHICH THE CYTOPLASMIC DOMAIN OF ENV CONTRIBUTES TO COUNTERACTION OF SERINC PROTEINS. WHEN THE PROPOSED EXPERIMENTS ARE COMPLETE, WE SHOULD HAVE A HIGH RESOLUTION MECHANISTIC UNDERSTANDING OF HOW NEF COUNTERACTS THE INHIBITORY INFLUENCE OF THE SERINC PROTEINS ON VIRAL INFECTIVITY, AND A MODEL FOR HOW THE ACTIVITY OF ENV IS INHIBITED BY THESE PROTEINS. 706756 DR. IX - KIDNEY TUBLAR DAMAGE AND DYSFUNCTION IDENTIFY A NOVEL AXIS OF CHRONIC KIDNEY:PATHOLOGIC STUDIES DEMONSTRATE THAT KIDNEY TUBULE INJURY, ATROPHY, AND FIBROSIS ARE COMMON FEATURES OF CHRONIC KIDNEY DISEASE (CKD) AND ARE HIGHLY PREDICTIVE OF PROGRESSION TO DIALYSIS. ESTABLISHED CKD RISK FACTORS INCLUDING HYPERTENSION AND ADVANCED AGE ARE ASSOCIATED WITH TUBULAR INJURY AND FIBROSIS ON BIOPSY. HOWEVER, CURRENT CLINICAL ASSESSMENT OF CKD EVALUATES ONLY GLOMERULAR FUNCTION (GFR) AND GLOMERULAR INJURY (ALBUMINURIA), BUT NOT KIDNEY TUBULAR DYSFUNCTION OR INJURY. THE OVERALL HYPOTHESIS OF THIS APPLICATION IS THAT KIDNEY TUBULAR DYSFUNCTION AND INJURY ARE MEASURABLE CONTRIBUTORS TO CKD PATHOGENESIS AND PROGNOSIS. DYSFUNCTION OF THE KIDNEY TUBULES WILL BE ASSESSED BY THREE INDICES: (1) RENAL TUBULE RESISTANCE TO HORMONE ACTIONS OF FGF23 AND PTH; (2) ACID/BASE HOMEOSTASIS; AND (3) URINE RE-ABSORPTIVE CAPACITY.WE WILL: (1) DETERMINE THE ASSOCIATION OF KIDNEY TUBULAR DYSFUNCTION AND INJURY WITH RISK OF CVD EVENTS, (2) DETERMINE THE ASSOCIATION OF KIDNEY TUBULAR DYSFUNCTION AND INJURY WITH CKD PROGRESSION, AND (3) DETERMINE WHETHER RANDOMIZATION TO INTENSIVE BLOOD PRESSURE MANAGEMENT ARM OF THE TRIAL SLOWS PROGRESSION OF KIDNEY TUBULAR DYSFUNCTION AND INJURY OVER TIME COMPARED WITH STANDARD BLOOD PRESSURE MANAGEMENT. 528901 DR. HAMMOND - DISCOVERY AND DEVELOPMENT OF THERAPEUTIC GENES FOR CHF.THE PURPOSE OF THIS PROGRAM, "DISCOVERY & DEVELOPMENT OF THERAPEUTIC GENES FOR CHF" IS TO ENABLE A NUMBER OF SCIENTISTS AT VMRF AND UCSD TO MAINTAIN AN EFFICIENT, INTERACTIVE AND MUTUALLY REINFORCING PROGRAM OF BASIC AND TRANSLATIONAL RESEARCH TO PROMOTE THE DISCOVERY AND DEVELOPMENT OF THERAPEUTIC GENES FOR CONGESTIVE HEART FAILURE (CHF) AND OTHER CARDIOVASCULAR DISEASES. THE PROGRAM WILL FACILITATE THE TRANSITION FROM DISCOVERY TO CLINICAL APPLICATION OF NEW THERAPEUTIC GENES. THIS MODEL COMBINES DISCOVERY RESEARCH WITH PRACTICAL "STREET-SMART" PRECLINICAL DEVELOPMENT. SUCCESSFULLY ATTAINING OUR GOALS WILL REQUIRE SEPARATE BUT HIGHLY INTEGRATED PROJECTS THAT CONTAIN THE PROPER PROPORTIONS OF DISCOVERY RESEARCH AND FOCUSED PRECLINICAL DEVELOPMENT, AN ACCOMPLISHED TRANSLATIONAL PHYSIOLOGY CORE, AND AN INTERACTIVE GROUP OF VMRF AND UCSD PHYSICIAN-SCIENTISTS IN AN IDEAL ENVIRONMENT. 8660680 4943731 VETERANS MEDICAL RESEARCH FOUNDATION OF SAN DIEGO, WHERE WE HONOR SERVICE WITH SCIENCE, IS THE REGION'S ONLY MEDICAL RESEARCH INSTITUTE DEDICATED TO VETERANS. WE FACILITATE WORLD-CLASS RESEARCH AT THE VA SAN DIEGO HEALTHCARE SYSTEM THAT PROVIDES IMPROVEMENTS FOR VETERANS' HEALTHCARE. WHILE FOCUSED ON VETERANS, OUR MEDICAL ADVANCES EXTEND TO THE ENTIRE POPULATION AND RAISE THE STANDARD OF CARE FOR EVERYONE. 8660680 4943731 11248632 1 1 0 1 0 0 0 0 0 0 1 0 0 0 0 1 1 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 28 0 1 194 1 0 0 0 0 0 0 0 0 0 0 0 0 X 14 13 0 0 0 0 0 1 1 1 1 0 0 1 1 1 1 1 1 1 1 0 CA X ADAM CASSIUS CFO 8586423069 3350 LA JOLLA VILLAGE DRIVE BLDG 13 SAN DIEGO CA 92161 PHILLIP L JELSMA CHAIRMAN 4.00 X X 30000 0 0 ELAINE MUCHMORE MD VICE PRESIDENT 1.00 X X 0 0 0 KATHLEEN KIM MD MPH DIRECTOR 1.00 X 0 0 0 WILLIAM CARON DIRECTOR 1.00 X 0 0 0 ERIC WILSON DIRECTOR 1.00 X 0 0 0 ROBIN SAMIT DIRECTOR 1.00 X 0 0 0 KIRK JORGENSEN DIRECTOR 1.00 X 0 0 0 ROBERT B HALDER MD DIRECTOR 1.00 X 0 0 0 BARBARA NOERENBERG DIRECTOR 1.00 X 0 0 0 GERHARD SCHULTEIS PHD DIRECTOR 1.00 X 0 0 0 ROBERT SMITH MD DIRECTOR 1.00 X 0 0 0 LEENDERT HERING RADM USN RET DIRECTOR 1.00 X 0 0 0 SHARON L FOSTER PH D DIRECTOR 1.00 X 0 0 0 ROBERT ANTHENELLI MD DIRECTOR 1.00 X 0 0 0 MARIA SITTMANN EXECUTIVE DIRECTOR/CEO 40.00 X 257635 0 46828 ADAM CASSIUS CFO (START 5/1/18) 40.00 X 124712 0 26410 RUTH HARBECKE RESEARCH ASSOCIATE 40.00 X 122883 0 40999 JEAN FREISER PRE AWARD DIRECTOR 40.00 X 100198 0 16849 MARI BRAY VMU DIRECTOR 40.00 X 104654 0 14595 MATTHEW DOEHNER POST AWARD DIRECTOR 40.00 X 107716 0 24995 MEI HAU GAO RESEARCH ASSOCIATE 40.00 X 104410 0 29488 952208 0 200164 7 0 1 0 REGENTS OF THE UNIVERSITY OF CALIFORNIA 9500 GILMAN DRIVE LA JOLLA CA 92093 LAB SERVICES 262676 LIFE TECHNOLOGIES CORPORATION 5781 VAN ALLEN WAY CARLSBAD CA 92008 LAB SERVICES 126988 2 9832753 55229 9887982 RECHARGE INCOME 541700 2771954 2771954 CLINICAL RESEARCH REVENUE 541700 1885559 1885559 GRANT REVENUE 541700 286218 286218 4943731 20280 20280 14851993 4943731 0 20280 516797 516797 9250979 7575162 1675817 251503 149808 101695 503743 315971 187772 419590 263406 156184 552694 122742 429952 22755 6701 16054 51500 51500 1360 1360 1505098 1335077 170021 1053027 967626 85401 155361 62597 92764 15248 15248 70824 66711 4113 72179 72179 89593 44395 45198 116096 6971 109125 211874 211874 BAD DEBTS 87496 82496 5000 SALES TAX 71229 66012 5217 OTHER EXPENSES 53082 39336 13746 PUBLICATION FEES 41656 41656 0 33819 29786 4033 15147503 11248632 3898871 0 2090485 1102096 500000 2499076 469577 537952 2208849 1766819 191910 212825 7563563 6981063 640661 582500 6101482 6701268 1888951 1770743 1100251 2113755 2989202 3884498 X 2928629 2671779 183651 144991 3112280 2816770 6101482 6701268 -295510 0 X 0 1 X 1 1 1 X 16690488 15134591 14599053 11430758 9887802 67742692 16690488 15134591 14599053 11430758 9887802 67742692 67742692 8660 17074 41544 12923 20280 100481 67843173 23385198 0.99850 0.99880 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 0 0 0 0 0 0 0 1 1360 1360 0 PART II-B, LINE 1: VMRF IS A MEMBER OF NAVREF (NATIONAL ASSOCIATION OF VETERAN RESEARCH & EDUCATION FOUNDATIONS), AIRI (ASSOCIATION OF INDEPENDENT RESEARCH INSTITUTES) AND CALIFORNIA CHAMBER OF COMMERCE AND A SMALL PORTION OF THE MEMBERSHIP AMOUNT IS ATTRIBUTED TO LOBBYING. 5747970 5283683 464287 1815593 1697380 118213 582500 X 14851993 0 14851993 0 14851993 15147503 0 15147503 0 15147503 PART X, LINE 2: THE ORGANIZATION RECOGNIZES ACCRUED INTEREST AND PENALTIES ASSOCIATED WITH UNCERTAIN TAX POSITIONS AS PART OF THE INCOME TAX PROVISION, WHEN APPLICABLE. THERE ARE NO AMOUNTS ACCRUED IN THE FINANCIAL STATEMENTS RELATED TO UNCERTAIN TAX POSITIONS FOR THE YEARS ENDED SEPTEMBER 30, 2019 AND 2018. EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 PROGRAM SERVICE TRONDHEIM & BERGEN RENAL CONFERENCE 8658 EAST ASIA AND THE PACIFIC 0 0 PROGRAM SERVICE ASNACC CONFERENCE AND TRAVEL FOR SLEEP STUDY SET-UP 5699 NORTH AMERICA 0 0 PROGRAM SERVICE OSTEOARTHRITIS RESEARCH SOCIETY INTERNATIONAL (OARSI) CONFERENCE 2451 0 0 0 0 0 0 16808 0 16808 0 0 0 0 0 0 X X X X X 0 0 0 0 0 0 0 0 0 MARIA SITTMANN EXECUTIVE DIRECTOR/CEO 257635 0 0 0 0 0 24500 0 22328 0 304463 0 0 0 ADAM CASSIUS CFO (START 5/1/18) 124712 0 0 0 0 0 0 0 26410 0 151122 0 0 0 RUTH HARBECKE RESEARCH ASSOCIATE 122883 0 0 0 0 0 13149 0 27850 0 163882 0 0 0 FORM 990, PART VI, SECTION A, LINE 7A THE VETERANS MEDICAL RESEARCH FOUNDATION BOARD OF DIRECTORS INCLUDES FOUR (4) MANDATORY BOARD MEMBERS REPRESENTING THE VA SAN DIEGO HEALTHCARE SYSTEM (VASDHS) AND ONE BOARD MEMBER REPRESENTING VA SOUTHERN NEVADA HEALTHCARE SYSTEM (VASNHS). THESE MEMBERS ARE THE VASDHS DIRECTOR, CHIEF OF STAFF, ASSOCIATE CHIEF OF STAFF FOR RESEARCH AND DEVELOPMENT, THE ASSOCIATE CHIEF OF STAFF FOR EDUCATION, AND THE VASNHS DIRECTOR. ALL OF THESE VAS LEADERS ARE ULTIMATELY HIRED AND APPROVED BY THE DEPARTMENT OF VETERANS AFFAIRS VETERANS HEALTH ADMINISTRATION. FORM 990, PART VI, SECTION A, LINE 7B THE VETERANS MEDICAL RESEARCH FOUNDATION'S BOARD MEMBERS MUST BE SPECIFICALLY APPROVED BY THE DIRECTOR OF VASDHS. THE DIRECTOR OF THE VASDHS IS A VOTING MEMBER OF THE VMRF BOARD OF DIRECTORS AND HAS THE SAME VOTING RIGHTS AS ALL OTHER VOTING MEMBERS. FORM 990, PART VI, SECTION B, LINE 11B AFTER INTERNAL REVIEW BY THE EXECUTIVE DIRECTOR, CFO, AND THE ACCOUNTING DIRECTOR, THE AUDITORS REVIEW THE 990 WITH THE AUDIT COMMITTEE. THE 990 IS THEN DISTRIBUTED TO THE BOARD PRIOR TO FINAL APPROVAL BY THE EXECUTIVE DIRECTOR AND CEO. FORM 990, PART VI, SECTION B, LINE 12C MEMBERS OF THE BOARD OF DIRECTORS AND EXECUTIVE OFFICERS ARE REQUIRED TO COMPLETE AND SIGN A COI DISCLOSURE QUESTIONNAIRE (INCLUDING DISCLOSURE PERTAINING TO SPOUSE OR DEPENDENT CHILDREN) AND TO SIGN A VMRF COI AFFIRMATION OF COMPLIANCE STATEMENT. VMRF'S POLICY ON COI INCLUDES DISCLOSURE REQUIREMENTS, PROCEDURES FOR REVIEW OF POTENTIAL CONFLICTS AND ADDRESSING CONFLICTS OF INTERESTS, AS WELL AS PROVISIONS ON WHAT DISCIPLINARY ACTIONS TO TAKE IN CASE OF VIOLATIONS OF THE BOARD APPROVED COI POLICY. INTERESTED PARTIES WITH A POTENTIAL COI RE: PROPOSED ACTION, POLICY, OR TRANSACTION OF VMRF SHALL NOT PARTICIPATE IN ANY WAY OR BE PRESENT DURING THE DELIBERATION AND DECISION-MAKING FOR SUCH ACTION. ALL ANNUAL BOARD AND KEY EMPLOYEE DISCLOSURE FORMS ARE REVIEWED BY THE EXECUTIVE DIRECTOR. IF THERE ARE CONFLICTS, THEY WILL BE MANAGED AS PER POLICY. THE EXECUTIVE DIRECTOR'S DISCLOSURE IS REVIEWED BY THE BOARD CHAIRMAN AND IF RESEARCH RELATED, BY THE INSTITUTIONAL INDEPENDENT REVIEW BOARD. FORM 990, PART VI, SECTION B, LINE 15 SALARIES OF EXECUTIVE OFFICERS WERE REVIEWED AND RECOMMENDED FOR BOARD APPROVAL BY THE COMPENSATION COMMITTEE. SALARY REVIEWS INCORPORATE PERFORMANCE REVIEW RESULTS AND JOB SPECIFIC COMPARISON SALARY DATA FROM LIKE ORGANIZATIONS, AS WELL AS TWO NATIONAL SALARY SURVEYS. THE TO-BE-EVALUATED PERSON DOES NOT PARTICIPATE IN THE SALARY DISCUSSION OR DECISION MAKING PROCESS AND IS EXCUSED FROM THAT PART OF THE MEETING(S). THE BOARD CHAIRMAN IS THE ONLY PAID BOARD MEMBER AND THE CHAIRMAN'S HONORARIUM WAS BOARD APPROVED. FORM 990, PART VI, SECTION C, LINE 18 IT IS NOTED ON THE WEBSITE THAT THESE DOCUMENTS ARE AVAILABLE UPON REQUEST BY CONTACTING THE VMRF CFO. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES THE A133 AUDITED FINANCIALS AVAILABLE ONLY IF REQUIRED BY A GRANTOR.